| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, Fmoc-N-amido-PEG2-alcohol itself has no intrinsic biological activity; it serves as a structural connector to join a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. The Fmoc-protected amine provides an orthogonal protecting group that can be selectively removed under basic conditions (e.g., 20% piperidine in DMF) without affecting most other functional groups. After deprotection, the free amine can be conjugated to a carboxylic acid-containing ligand via amide bond formation using EDC/NHS or HATU. The terminal hydroxyl group can be converted to a leaving group (e.g., tosylate or mesylate) for nucleophilic substitution, or oxidized to a carboxylic acid for amide bond formation. The orthogonal functional groups enable stepwise conjugation to two different ligands. The PEG2 spacer provides a short, hydrophilic, and flexible connection, which can facilitate the formation of productive ternary complexes. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥98%. The Fmoc group can be characterized by its characteristic aromatic proton signals in NMR spectroscopy (e.g., multiplets around 7.2-7.8 ppm) and by its UV absorption at 265 nm and 301 nm. The hydroxyl group can be characterized by its chemical shift in NMR (a broad peak around 2-5 ppm depending on solvent). The IUPAC name is 9H-fluoren-9-ylmethyl N-[2-(2-hydroxyethoxy)ethyl]carbamate.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical two-step synthesis, the Fmoc group is removed with piperidine, and the resulting free amine is conjugated to a carboxylic acid-containing ligand (e.g., an E3 ligase ligand) via amide bond formation using EDC and NHS. The terminal hydroxyl group is then converted to a tosylate or mesylate and displaced by a nucleophile from a target protein ligand, or oxidized to a carboxylic acid and coupled to an amine-containing ligand. The resulting PROTAC is then tested in cells for target degradation activity.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The PEG2 spacer may improve the pharmacokinetic properties of the conjugate by enhancing water solubility.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 327.37-327.38, a molecular formula of C19H21NO4, and a standard purity of ≥98%. It appears as a solid at room temperature. For storage, it should be kept as a powder at -20degC for up to 3 years or in a solvent at -80degC for 6 months. It is soluble in DMSO and other organic solvents. The product should be stored in a sealed container, away from moisture. The IUPAC name is 9H-fluoren-9-ylmethyl N-[2-(2-hydroxyethoxy)ethyl]carbamate. CAS: 299430-87-8.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The product is stable under recommended storage conditions. It is not an approved therapeutic drug and has not been cleared for clinical use. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
The Fmoc protecting group is widely used in solid-phase peptide synthesis and can be removed under mild basic conditions without affecting acid-labile protecting groups. This makes Fmoc-N-amido-PEG2-alcohol a versatile building block for the stepwise synthesis of PROTACs and other bioconjugates using solid-phase or solution-phase methodologies. The short PEG2 spacer provides a minimal hydrophilic linker that is ideal for target-E3 ligase pairs that require a short, rigid spacer for optimal ternary complex formation. The combination of an Fmoc-protected amine and a terminal hydroxyl group provides orthogonal functional groups for sequential conjugation to two different ligands. This compound is also known as 2-[2-(Fmoc-amino)ethoxy]ethanol and Fmoc-PEG2-alcohol.
|
| Molecular Formula |
C19H21NO4
|
|---|---|
| Molecular Weight |
327.37
|
| Exact Mass |
327.147
|
| CAS # |
299430-87-8
|
| Related CAS # |
179398-62-0
|
| PubChem CID |
11416167
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.221g/cm3
|
| Boiling Point |
547.8ºC at 760 mmHg
|
| Flash Point |
285.1ºC
|
| Vapour Pressure |
7.81E-13mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
2.924
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
24
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NCCOCCO
|
| InChi Key |
DUVHQSUZTXSLMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H21NO4/c21-10-12-23-11-9-20-19(22)24-13-18-16-7-3-1-5-14(16)15-6-2-4-8-17(15)18/h1-8,18,21H,9-13H2,(H,20,22)
|
| Chemical Name |
9H-fluoren-9-ylmethyl N-[2-(2-hydroxyethoxy)ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0546 mL | 15.2732 mL | 30.5465 mL | |
| 5 mM | 0.6109 mL | 3.0546 mL | 6.1093 mL | |
| 10 mM | 0.3055 mL | 1.5273 mL | 3.0546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
